Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/28/2025

Pediatric Acute Otitis Media Diagnosis and Management Guidelines

Diagnostic Criteria

  • Acute otitis media (AOM) is diagnosed when a child has (1) an acute onset of ear‑related symptoms, (2) evidence of middle‑ear effusion, and (3) otoscopic signs of middle‑ear inflammation such as a bulging tympanic membrane 1.

Treatment Algorithm by Age

Infants < 6 Months

  • All infants younger than 6 months with confirmed AOM should receive immediate antibiotic therapy; observation is not recommended because of higher complication risk and difficulty monitoring clinical status 2.
  • Recommended regimen: high‑dose amoxicillin 80–90 mg/kg/day divided twice daily for 10 days (the 10‑day course is mandatory for children < 2 years) 2.

Children 6–23 Months

  • Immediate antibiotics are indicated for bilateral AOM or for AOM with otorrhea and middle‑ear effusion 1.
  • Watchful waiting is acceptable for unilateral AOM with mild symptoms (mild ear pain and fever < 39 °C) provided reliable follow‑up can be arranged within 48–72 hours 1.

Children ≥ 2 Years

  • Immediate antibiotics are advised for severe symptoms (moderate‑to‑severe ear pain or fever ≥ 39 °C), for otorrhea with effusion, or when reliable follow‑up cannot be guaranteed 1.
  • Observation may be chosen for non‑severe unilateral or bilateral AOM when a dependable 48–72 hour follow‑up is available 1.

First‑Line Antibiotic Selection

  • High‑dose amoxicillin (80–90 mg/kg/day divided twice daily, max 2 g per dose) is the first‑line therapy for most children with AOM 1.
  • This dosing achieves middle‑ear fluid concentrations that overcome penicillin‑resistant Streptococcus pneumoniae (≈ 35 % of isolates) and also covers beta‑lactamase‑negative Haemophilus influenzae and Moraxella catarrhalis 2.

When to Use Amoxicillin‑Clavulanate First‑Line

  • Switch to amoxicillin‑clavulanate (amoxicillin component 90 mg/kg/day + clavulanate 6.4 mg/kg/day) if the child received amoxicillin within the past 30 days, has concurrent purulent conjunctivitis, lives in an area with high beta‑lactamase‑producing pathogen prevalence, or attends daycare 1.
  • Twice‑daily dosing of amoxicillin‑clavulanate results in significantly less diarrhea than three‑times‑daily dosing while maintaining efficacy 2.

Penicillin‑Allergy Alternatives

  • For non‑IgE‑mediated penicillin allergy, preferred oral options include cefdinir 14 mg/kg once daily, cefuroxime 30 mg/kg twice daily, or cefpodoxime 10 mg/kg twice daily 2.
  • Cross‑reactivity between penicillins and second/third‑generation cephalosporins is low, making these agents generally safe 1.
  • For IgE‑mediated (severe) penicillin allergy, azithromycin may be used, recognizing it is less effective than amoxicillin for AOM 4.
  • Trimethoprim‑sulfamethoxazole and erythromycin‑sulfisoxazole should be avoided because of high resistance rates 1.

Treatment Duration

  • Children < 2 years: 10 days of therapy for all episodes, regardless of severity 1.
  • Children 2–5 years with mild‑moderate symptoms: 7 days; with severe symptoms: 10 days 4.
  • Children ≥ 6 years with mild‑moderate symptoms: 5–7 days; with severe symptoms: 10 days 4.

Pain Management (Mandatory for All Patients)

  • Analgesia must be provided immediately; antibiotics do not relieve pain in the first 24 hours, and about 30 % of children < 2 years have persistent pain or fever after 3–7 days of therapy 1.
  • Use age‑appropriate acetaminophen or ibuprofen, continued for at least the first 24–48 hours of illness 2.
  • Topical analgesic ear drops may give rapid relief (10–30 minutes), though supporting evidence is limited 2.

Management of Treatment Failure

  • Re‑evaluate the child at 48–72 hours if symptoms worsen or fail to improve; confirm the diagnosis with proper tympanic‑membrane visualization 1.
  • If the initial regimen was amoxicillin, switch to amoxicillin‑clavulanate (amoxicillin component 90 mg/kg/day) 1.
  • If the initial regimen was amoxicillin‑clavulanate, change to intramuscular ceftriaxone 50 mg/kg once daily for 1–3 days (maximum 1–2 g). A 3‑day course is superior to a 1‑day course 1.
  • After multiple failures, consider tympanocentesis with culture and susceptibility testing; if unavailable, use clindamycin (with or without coverage for H. influenzae and M. catarrhalis) 1.
  • For multidrug‑resistant S. pneumoniae serotype 19A, levofloxacin or linezolid may be used after specialist consultation 2.

Post‑Treatment Follow‑Up

  • Middle‑ear effusion persists in 60–70 % of children at 2 weeks, 40 % at 1 month, and 10–25 % at 3 months after successful therapy; routine antibiotics are not indicated unless effusion lasts > 3 months with documented hearing loss 1.
  • Routine follow‑up visits are not required for all children; consider reassessment for infants < 6 months, children with severe initial presentations, those with recurrent AOM, children with developmental delays, or when parents express concern 1.

Recurrent AOM Management

  • Recurrent AOM is defined as ≥ 3 episodes in 6 months or ≥ 4 episodes in 12 months with at least one episode in the preceding 6 months 1.
  • Preventive measures: administer pneumococcal conjugate vaccine (PCV‑13) and annual influenza vaccine, encourage exclusive breastfeeding for at least 6 months, limit pacifier use after 6 months, avoid supine bottle feeding, eliminate tobacco‑smoke exposure, and reduce daycare attendance when feasible 1.
  • Surgical option: tympanostomy tubes are indicated for children meeting the recurrent‑AOM criteria; failure rates are ~21 % for tubes alone and ~16 % for tubes combined with adenoidectomy 2.
  • Long‑term prophylactic antibiotics are not recommended because modest benefit does not outweigh the risk of antimicrobial resistance 2.

Critical Pitfalls to Avoid

  • Do not prescribe antibiotics for isolated tympanic‑membrane redness without bulging or effusion 3.
  • Do not use topical antibiotics for AOM (they are reserved for otitis externa or tube otorrhea) 2.
  • Do not use systemic corticosteroids for AOM; evidence shows no benefit 2.
  • Do not use trimethoprim‑sulfamethoxazole or erythromycin‑sulfisoxazole due to high resistance 1.
  • Antibiotics do not eliminate the risk of mastoiditis; 33–81 % of mastoiditis cases had received antibiotics previously 2.
  • Do not treat post‑AOM effusion (OME) with antibiotics unless it persists > 3 months and is associated with hearing loss 1.

REFERENCES

2

Treatment of Acute Otitis Media [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3

Acute Otitis Media Treatment Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4

Treatment for Acute Otitis Media in Infants [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026